Concepedia

Publication | Open Access

Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial

DOIFull Paper Access

97

Citations

15

References

2022

Year

Chung‐Han Lee, Robert J. Motzer, Hamid Emamekhoo, Marc Matrana, Ivor Percent, James J. Hsieh, Arif Hussain, Ulka N. Vaishampayan, Sandy Liu, Steven McCune,
Clinical Cancer Research

Abstract

TelaE was well tolerated and improved PFS versus PboE in patients with mRCC previously treated with TKIs and checkpoint inhibitors.

References

YearCitations

Page 1